6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias

Quantitative Platelet Disorders & Immune Thrombocytopenias

Quantitative platelet disorders encompass conditions in which the total number of circulating platelets is decreased (thrombocytopenia, platelet count $<150 \times 10^9/\text{L}$ [$<150,000/\mu\text{L}$]) or increased (thrombocytosis, platelet count $>450 \times 10^9/\text{L}$ [$>450,000/\mu\text{L}$]). Thrombocytopenia is the most common cause of abnormal bleeding encountered in clinical laboratory practice, arising from four fundamental pathophysiological mechanisms:

1. Decreased bone marrow production (e.g., aplastic anemia, myelodysplasia, acute leukemia, chemotherapy, nutritional $B_{12}$/folate deficiency).
2. Accelerated peripheral destruction (immune-mediated such as ITP, HIT, NAIT; or non-immune consumptive such as TTP, HUS, DIC).
3. Abnormal splenic sequestration / pooling (hypersplenism, portal hypertension, cirrhotic splenomegaly).
4. Hemodilution (massive transfusion protocols with packed red cells and crystalloids lacking platelets).

                  ┌─────────────────────────────────────────┐
                  │   THROMBOCYTOPENIA (<150 x 10^9/L)      │
                  └────────────────────┬────────────────────┘
                                       │
       ┌───────────────────────┬───────┴───────────────┬───────────────────────┐
       ▼                       ▼                       ▼                       ▼
[ PRODUCTION DEFICIT ]  [ CONSUMPTION / DESTR ]  [ SEQUESTRATION ]      [ SPURIOUS / ARTIFACT ]
• Aplastic Anemia       • Immune: ITP, HIT,      • Hypersplenism        • EDTA-dependent
• Marrow Infiltration     NAIT, PTP, Drug-induced  (Cirrhosis, Portal     Agglutination
• Megaloblastic Anemia  • Microangiopathic:        Hypertension)        • Platelet Satellitism
• Chemotherapy / Toxins   TTP, HUS, DIC          • Splenomegaly         • Giant Platelets / RBCs

---

Clinical Bleeding Risk & Platelet Count Thresholds

---

Pseudothrombocytopenia (EDTA-Dependent Platelet Agglutination)

Pseudothrombocytopenia (spurious thrombocytopenia) is an in vitro laboratory artifact with an incidence of approximately 0.1% to 0.2% in routine automated complete blood count (CBC) testing. It possesses no in vivo clinical bleeding risk but can lead to misdiagnosis, unnecessary bone marrow biopsies, or inappropriate platelet transfusions if unrecognized.

                               [ EDTA ARTIFACT MECHANISM ]

  Patient Plasma IgG/IgM Autoantibody
                 │
                 ▼
  EDTA Tube ──► Chelates Ca2+ ──► Alters Platelet GPIIb/IIIa Conformation ──► Exposes Cryptic Neoepitopes
                                                                                       │
                                                                                       ▼
  Platelet Clumping in Vitro ◄────────────────────────────────────────────── IgG Autoantibody Binds
                 │
                 ▼
  Automated Analyzer Counts Clumps as WBCs ──► [ FALSE LEUKOCYTOSIS + SEVERE FALSE THROMBOCYTOPENIA ]

Molecular Pathophysiology & Automated Analyzer Artifact

• Immunological Basis: The patient's serum contains naturally occurring IgG, IgM, or IgA autoantibodies directed against cryptic epitopes on Glycoprotein IIb/IIIa (integrin $\alpha_{IIb}\beta_3$).
• Calcium Chelation Trigger: In the presence of ethylenediaminetetraacetic acid (EDTA, purple-top tube), divalent calcium ($Ca^{2+}$) is chelated from the platelet membrane. This induces a structural dissociation or allosteric change in GPIIb/IIIa, unmasking normally hidden (cryptic) antigenic sites. The autoantibodies bind these neoepitopes, causing extensive in vitro platelet agglutination (clumping).
• Coulter / Optical Analyzer Distortion: Automated cell counters utilize electrical impedance or optical light scatter to enumerate particles by size. Large platelet clumps exceed the platelet size threshold ($2\text{ to }20\text{ fL}$) and are registered in the lymphocyte / leukocyte size channel. This causes a profound false thrombocytopenia (often reporting platelets $<20 \times 10^9/\text{L}$) paired with a spurious false leukocytosis (pseudoleukocytosis).
• Platelet Satellitism: A related morphologic phenomenon where EDTA-dependent autoantibodies direct platelets to rosette around the outer membrane of mature segmented neutrophils and bands. Neutrophils phagocytose occasional adhering platelets.

Diagnostic Verification & Corrective Protocol

1. Peripheral Smear Examination: Review of a Wright-stained blood film made from the EDTA tube immediately reveals large aggregates and clumps of platelets, particularly along the feathered edge and lateral borders, or classic platelet satellitism around neutrophils.
2. Specimen Recollection in Sodium Citrate: Redraw a fresh blood specimen in a 3.2% sodium citrate tube (light blue top). Citrate does not expose the EDTA-dependent cryptic neoepitopes, permitting platelets to remain in a monodisperse suspension.
3. Dilution Correction Factor (1.1x Multiplier): Liquid sodium citrate anticoagulant occupies 10% of the tube volume (1 part citrate to 9 parts whole blood, causing a 10% dilution). The technologist must multiply the raw automated platelet count obtained from the citrate tube by 1.1 (or $10/9$) before reporting the verified value in the laboratory information system (LIS).

$\text{Reportable Platelet Count} = \text{Citrate Analyzer Platelet Count} \times 1.1$

---

Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (formerly Idiopathic Thrombocytopenic Purpura) is an acquired autoimmune disorder characterized by isolated thrombocytopenia ($<100 \times 10^9/\text{L}$) in the absence of other systemic causes or cytopenias.

                                  [ ITP PATHOGENESIS ]

           Autoreactive B-Cells Synthesize Anti-Platelet IgG Autoantibodies
                 (Directed against GPIIb/IIIa [CD41/CD61] or GPIb/IX [CD42])
                                           │
                   ┌───────────────────────┴───────────────────────┐
                   ▼                                               ▼
       [ SPLEEN: PERIPHERAL DESTRUCTION ]             [ MARROW: PRODUCTION SUPPRESSION ]
     - IgG-opsonized platelets circulate            - Autoantibodies bind Megakaryocyte
       into splenic red pulp cords                    GPIIb/IIIa & GPIb/IX receptors
     - Splenic macrophages bind Fc domain           - Induces megakaryocyte apoptosis
       via FcγRIIa / FcγRIIIa receptors             - Blunts compensatory thrombopoiesis
     - Phagocytosis & premature destruction

Acute vs. Chronic ITP

Bone Marrow Findings in ITP

• Bone marrow aspiration is performed in atypical presentations or adults over 60 to exclude myelodysplastic syndromes or leukemia.
• Findings show normal to markedly increased numbers of megakaryocytes (megakaryocytic hyperplasia) attempting to compensate for peripheral destruction.
• Megakaryocytes exhibit young, immature features: single or hypolobated nuclei, basophilic cytoplasm, and reduced platelet budding.
• Erythroid and myeloid maturation sequences are entirely normal.

---

Drug-Induced & Heparin-Induced Thrombocytopenia (HIT)

HIT Type I vs. HIT Type II

Molecular Mechanism of HIT Type II: The Paradoxical Thrombosis

                                  [ HIT TYPE II CASCADE ]

  1. Positively charged Platelet Factor 4 (PF4) tetramers bind negatively charged polyanionic Heparin
                                           │
                                           ▼
  2. Multimolecular PF4-Heparin complexes expose conformational Neoepitopes
                                           │
                                           ▼
  3. Patient synthesizes IgG Autoantibodies against PF4-Heparin complexes
                                           │
                                           ▼
  4. IgG-PF4-Heparin immune complexes bind platelet FcγRIIa (CD32) receptors via their Fc domain
                                           │
                                           ▼
  5. Massive In Vivo Platelet Activation ──► Microparticle Release ──► Explosive Thrombin Generation
                                           │
                   ┌───────────────────────┴───────────────────────┐
                   ▼                                               ▼
        [ CONSUMPTIVE THROMBOCYTOPENIA ]                 [ DEVASTATING THROMBOSIS (HITT) ]
        - Platelet clearance & consumption               - "White Clots", DVT, PE
        - Platelets drop >50%                            - Stroke, MI, Limb Gangrene

• Platelet Factor 4 (PF4): A positively charged tetrameric chemokine stored in platelet $\alpha$-granules. When heparin (a highly negatively charged polyanion) is administered, it binds PF4, forming multimolecular PF4-heparin complexes that expose immunogenic neoepitopes.
• Fc Receptor Crosslinking: Patients generate IgG antibodies that bind PF4-heparin. The Fc tail of these IgG molecules binds $Fc\gamma RIIa$ (CD32) receptors on platelet surfaces. This crosslinking triggers intense platelet activation, shape change, granule discharge, procoagulant microparticle shedding, and systemic thrombin generation.
• The Paradoxical Clinical Presentation: Although platelet counts drop (due to clearance of opsonized platelets and microvascular consumption), the patient is in an intensely hypercoagulable, prothrombotic state. Patients present with Heparin-Induced Thrombocytopenia and Thrombosis (HITT), developing venous thromboembolism (deep vein thrombosis, pulmonary embolism) and arterial occlusions (limb ischemia, stroke, myocardial infarction, "white clot syndrome").

Diagnostic Evaluation: The 4T Score & Laboratory Testing

• The 4T Pretest Probability Score: Evaluates four clinical categories (each scored 0–2 points): Thrombocytopenia ($>50%$ drop), Timing of onset (days 5–10), Thrombosis (proven new thrombosis or skin necrosis), and oTher causes excluded. Scores 6–8 indicate high probability.
• Screening Assay (Polyspecific / IgG PF4 ELISA): High diagnostic sensitivity ($>98%$) but lower specificity; detects anti-PF4/heparin antibodies.
• Confirmatory Gold Standard (Functional Assay): Serotonin Release Assay (SRA). Washed normal donor platelets are incubated with radioactive $^{14}\text{C}$-serotonin, patient serum, and low ($0.1\text{--}0.5\text{ U/mL}$) vs high ($100\text{ U/mL}$) heparin concentrations. Therapeutic low heparin produces $>20%$ serotonin release, which is competitively suppressed to baseline by supratherapeutic high heparin ($100\text{ U/mL}$). Alternatively, Heparin-Induced Platelet Aggregation (HIPA) is utilized.

Urgent Management Rules in Acute HIT

1. Cease All Heparin Immediately: Discontinue unfractionated heparin infusions, subcutaneous heparin, low-molecular-weight heparins (enoxaparin, dalteparin), and heparin flush solutions.
2. Initiate Non-Heparin Anticoagulant: Immediately start an intravenous direct thrombin inhibitor (DTI) such as Argatroban (cleared hepatically, ideal for renal impairment) or Bivalirudin (cleared renally/enzymatically), or subcutaneously administer Fondaparinux (synthetic pentasaccharide FXa inhibitor).
3. Strict Warfarin Contraindication: Warfarin is absolutely contraindicated during acute HIT. Warfarin rapidly depletes short-half-life Protein C (~8 hours) before significantly suppressing prothrombin (~60 hours). This creates an extreme imbalance of unopposed thrombin generation in microvessels, precipitating microvascular thrombosis, venous limb gangrene, and necrotic skin infarction. Warfarin may only be safely introduced after the patient is fully anticoagulated with a DTI and the platelet count has recovered to $\ge 150 \times 10^9/\text{L}$.

---

Neonatal Alloimmune Thrombocytopenia (NAIT) vs. Post-Transfusion Purpura (PTP)

• Neonatal Alloimmune Thrombocytopenia (NAIT / FNAIT):
  • Mechanism: Fetus inherits a paternal human platelet antigen (HPA) that the mother lacks. Fetal platelets enter maternal circulation, stimulating maternal IgG alloantibody production. Maternal IgG crosses the placenta and destroys fetal platelets.
  • Target Antigen: Anti-HPA-1a ($Pl^{A1}$) accounts for $\approx 80%$ of cases in Caucasian populations; anti-HPA-5b is second.
  • Clinical Impact: Unlike Rh hemolytic disease of the fetus/newborn, NAIT affects the FIRST pregnancy in up to 50% of cases. Severe fetal thrombocytopenia carries a 10% to 20% risk of catastrophic antenatal intracranial hemorrhage.
• Post-Transfusion Purpura (PTP):
  • Mechanism: A rare, severe delayed transfusion reaction occurring 5 to 10 days following transfusion of platelet- or RBC-containing blood products. Occurs almost exclusively in multiparous, HPA-1a negative females who were sensitized by prior pregnancy.
  • Autologous Destruction: Transfusion triggers an anamnestic surge in anti-HPA-1a alloantibodies. Paradoxically, the alloantibody destroys not only the transfused HPA-1a positive platelets, but also leads to innocent-bystander destruction of the patient's own autologous HPA-1a negative platelets, causing profound thrombocytopenia ($<10 \times 10^9/\text{L}$) and life-threatening bleeding. Treated with IVIG or plasmapheresis.